CRYPTIVAX
Live / Allowed — Notice of allowance issued (as of 13 Jan 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 03 Apr 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99118774
- Mark type
- Stylized text
- Filed
- 03 Apr 2025
- Published for opposition
- 18 Nov 2025
- Attorney of record
- Scott Locke
Goods and services
- Class 001 — Chemicals: Active chemical ingredients for use in the manufacture of anti-cancer therapeutics and vaccines; monoclonal antibodies for scientific purposes; nucleotides for scientific and research use; Chemicals, reagents and substances being peptides, nucleic acids and buffers for medical research purposes; proteins, namely arrays, monoclonal antibodies and enzymes for scientific and research use
- Class 005 — Pharmaceuticals: Immunoassay reagents for medical use; Pharmaceutical products for the prevention and treatment of cancer; vaccines for the treatment of cancer; vaccines for the prevention of cancer; antigens in the nature of tumor antigens for medical use; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; vaccines for regulating the immune system; pharmaceutical preparations for treatment in the nature of regulating the immune system; proteins with diagnostic and therapeutic uses, namely arrays and solutions of proteins for diagnosing cancer and diseases and disorders of the immune system; Antibodies for medical purposes; vaccines for the prevention and treatment of immune system related diseases and disorders
- Class 042 — Scientific and technological services: Research and development in the field of cancer; research and development in the field of immunology; scientific research for medical purposes in the field of oncology; scientific research for medical purposes in the field of immunology; Biological research services; Pharmaceutical research services; pharmaceutical, biologic and immunological drug and vaccine development services; providing scientific research information and data relating to oncology and immunology; advisory and consultancy services related to scientific research in the fields of oncology oncology and immunology
Owner
- Epitopea Ltd., Cambridge, GB
- Epitopea Ltd., Cambridge, GB
- Epitopea Inc., Montreal, QC, CA
- Epitopea Inc., Montreal, QC, CA
Prosecution history
- 21 Jan 2026 — TEAS DELETE 1(B) BASIS RECEIVED
- 13 Jan 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 18 Nov 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 18 Nov 2025 — PUBLISHED FOR OPPOSITION
- 12 Nov 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 10 Oct 2025 — WITHDRAWN FROM PUB - OG REVIEW QUERY
- 08 Oct 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 18 Sept 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 17 Sept 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 17 Sept 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 17 Sept 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 03 Sept 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 03 Sept 2025 — NON-FINAL ACTION E-MAILED
- 03 Sept 2025 — NON-FINAL ACTION WRITTEN
- 01 Sept 2025 — ASSIGNED TO EXAMINER